SCHEMBL326780

SCHEMBL326780

O=C(OCc1ccccc1)N1CCc2ccc([N+](=O)[O-])cc2C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 17/20 0.64
SIGMAR1 Q99720 17/20 0.64
HRH2 P25021 4/20 0.57
HTR2C P28335 4/20 0.57
HRH1 P35367 4/20 0.57
ADRA2A P08913 3/20 0.57
ADRA2B P18089 3/20 0.57
HRH3 Q9Y5N1 3/20 0.57
HTR1A P08908 3/20 0.57
HTR2A P28223 3/20 0.57
HTR2B P41595 3/20 0.57
DRD3 P35462 2/20 0.57
CHRM5 P08912 2/20 0.57
ADRA1D P25100 2/20 0.57
CHRM4 P08173 1/20 0.57
ADRA1A P35348 1/20 0.57
ADRA1B P35368 1/20 0.57
HTR5A P47898 1/20 0.57
HTR1E P28566 3/20 0.56
HTR1B P28222 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945831 0.94 TMEM97 (0.56) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL1506485 0.92 TMEM97 (0.58) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL30515329 0.84 TMEM97 (0.70) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL1299903 0.84 TMEM97 (0.70) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL6394885 0.83 ALDH1A1 (0.58) CPT2CPT1AMEN1KMT2AHPGD
SCHEMBL324228 0.83 TMEM97 (0.67) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL30422134 0.83 TMEM97 (0.49) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL16935069 0.83 DHFR (0.56) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL325572 0.82 TMEM97 (0.67) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL14101174 0.82 TMEM97 (0.67) TMEM97SIGMAR1HRH2HTR2CHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590942-B1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-05-04 EP disclosed
EP-2590942-B1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-05-04 EP disclosed
US-9079880-B2 Rho kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-07-14 US disclosed
US-9079880-B2 Rho kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-07-14 US disclosed
EP-2590942-A1 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2013-05-15 EP disclosed
US-20120178752-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-12 US disclosed
US-20120178752-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-12 US disclosed
WO-2012006202-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-12 WO disclosed
WO-2012006202-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-12 WO disclosed
US-20050154011-A1 Tetrahydroisoquinolnyl sulfamic acids THE PROCTER & GAMBLE COMPANY 2005-07-14 US disclosed
WO-2004074256-A1 TETRAHYDROISOQUINOLINYL SULFAMIC ACIDS THE PROCTER & GAMBLE COMPANY (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154011-A1 Tetrahydroisoquinolnyl sulfamic acids PTPRS, PTPRJ, PTPRM TMEM97 3135/4885SIGMAR1 4488/4885HRH2 3023/4885
US-20120178752-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, RHOA TMEM97 2122/4885SIGMAR1 1769/4885HRH2 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.